Table 2 Comparison of the MetS cases with and without COVID-19 infection and related association analyses
Characteristic | MetS patients with COVID-19 (N = 206) | MetS patients without COVID-19 (N = 794) | OR (95% CI) | P value |
|---|---|---|---|---|
Gender; Male/ Female (N, %) | 88 (42.8%)/ 118 (57.2%) | 378 (47.6%)/ 416 (52.4%) | 0.82 (0.60–1.11) | 0.2118 |
Smoker/ Non-smoker | 160 (77.6%)/46 (22.4%) | 324 (40.8%)/ 470 (59.2%) | 5.04 (3.53–7.21) | < 0.0001 |
Familial history of CVD (Yes/No) | 41 (19.9%)/ 165 (80.1%) | 108 (13.6%)/ 686 (86.4%) | 1.57 (1.06–2.34) | 0.0245 |
Age (Year, mean ± SD) | 51.5 ± 11.8 | 50.7 ± 10.2 | - | 0.8480 |
Duration of MetS (Year) | 14.8 ± 8.5 | 14.1 ± 8.9 | - | 0.3240 |
Systolic BP | 133.4 ± 21.4 | 128.3 ± 24.5 | - | 0.0018 |
Diastolic BP | 74.2 ± 6.7 | 72.4 ± 7.3 | - | 0.0014 |
WBC; cells/mm3 | 9581.6 ± 2219.2 | 5174.4 ± 1408.9 | - | < 0.0001 |
Lymphocyte-total leukocyte ratio | 24.3 ± 14.5 | 29.3 ± 14.1 | - | < 0.0001 |
Neutrophil-lymphocyte ratio | 8.4 ± 10.2 | 11.8 ± 14.5 | - | 0.0016 |
ALP (IU/L) | 318.9 ± 50.1 | 112.7 ± 38.6 | - | < 0.0001 |
AST (IU/L) | 31.5 ± 9.4 | 20.5 ± 5.4 | - | < 0.0001 |
ALT (IU/L) | 40.3 ± 10.6 | 25.7 ± 6.9 | - | < 0.0001 |
LDH (IU/L) | 439.5 ± 93.2 | 210.2 ± 65.8 | - | < 0.0001 |
CRP (mg/L) | 5.7 ± 2.1 | 1.4 ± 0.5 | - | < 0.0001 |
ESR (mm/h) | 21.3 ± 14.9 | 8.4 ± 5.8 | - | < 0.0001 |
BMI (kg/m2) | 31.4 ± 5.6 | 27.5 ± 4.7 | - | 0.0001 |
WC-Male (cm) | 101.8 ± 15.5 | 97.4 ± 14.1 | - | 0.0001 |
WC-Female (cm) | 96.2 ± 13.7 | 93.4 ± 13.1 | - | 0.0069 |
Total cholesterol (mg/dl) | 204.9 ± 38.7 | 198.6 ± 35.1 | - | 0.0249 |
TG (mg/dl) | 164.3 ± 58.2 | 149.8 ± 55.8 | - | 0.0010 |
LDL (mg/dl) | 135.4 ± 39.5 | 121.6 ± 36.4 | - | 0.0001 |
HDL (mg/dl) | 48.7 ± 12.1 | 49.5 ± 16.2 | - | 0.5079 |
Creatinine (mg/dl) | 1.80 ± 0.5 | 1.4 ± 0.29 | - | 0.0001 |
BUN | 25.4 ± 8.9 | 20.1 ± 7.3 | - | 0.0001 |
FBS (mg/dl) | 98.6 ± 29.5 | 93.8 ± 27.2 | - | 0.0268 |